Intraday mover · APGE · Healthcare

Apogee Therapeutics (APGE) surges 46.7% in active-mover trading

The biotechnology stock’s move puts fresh focus on a recent weekly advance that had already been building before the latest screen spike.

Apogee Therapeutics, Inc. Common Stock
Latest90.38 USD
1W move2.3%
Volume1.1x
TrendActive
Biotechnology lab and market data terminal representing Apogee Therapeutics shares in active trading.

Market update

What happened

Apogee Therapeutics (APGE) traded at 132.55 USD on the active-mover screen, up 42.17 USD, or 46.7%, with 61.2 million shares changing hands. The Waltham, Massachusetts biotechnology company develops biologics for atopic dermatitis, COPD, and related inflammatory and immunology indications.

The weekly backdrop was already positive but less extreme: market data showed a latest weekly close of 90.38 USD through June 19, with gains of 2.3% over one week, 11.4% over four weeks, and 16.1% over twelve weeks. The trend signal is active and Market Dynamics is providing confirmation, while Relative Strength at 18.8 and latest weekly volume at just 1.06 times the 13-week average leave the evidence mixed. No intraday chart is available for the move.

Continue your research

Explore APGE across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.

Biotechnology coverage

Evidence context